Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Strong Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Buy

Wall Street Data Solutions Rating

Neutral

B

Structure Therapeutics Inc. American Depositary Shares (GPCR)

Pharmaceutical Preparations

https://www.structuretx.com

Structure Therapeutics Inc is a clinical-stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.

611 GATEWAY BLVD SUITE 223
SOUTH SAN FRANCISCO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

02/03/2023

Market Cap

2,151,726,047

Shares Outstanding

136,760,000

Weighted SO

46,386,438

Total Employees

N/A

Upcoming Earnings

08/08/2024

Beta

-5.1329

Last Div

0.0000

Range

26.61-75.017

Chg

1.1100

Avg Vol

1209685

Mkt Cap

2151726047

Exch

NASDAQ

Country

US

Phone

628-229-9277

DCF Diff

33.6850

DCF

3.3850

Div Yield

0.0000

P/S

1617.8805

EV Multiple

-14.5829

P/FV

2.0182

Div Yield %

0.0000

P/E

-18.4831

PEG

0.2488

Payout

0.0000

Current Ratio

41.3796

Quick Ratio

41.3796

Cash Ratio

16.8422

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

412.8315

CCC

-412.8315

Gross Margin

-0.4685

Op Margin

-92.2168

Pretax Margin

-75.4914

Net Margin

-75.6214

Eff Tax Rate

-0.0017

ROA

-0.1062

ROE

-0.2015

ROCE

-0.1327

NI/EBT

1.0017

EBT/EBIT

0.8186

EBIT/Rev

-92.2168

Debt Ratio

0.0049

D/E

0.0051

LT Debt/Cap

0.0033

Total Debt/Cap

0.0050

Int Coverage

-6.7118

CF/Debt

-22.0062

Equity Multi

1.0282

Rec Turnover

0.0000

Pay Turnover

0.8841

Inv Turnover

0.0000

FA Turnover

0.1754

Asset Turnover

0.0014

OCF/Share

-2.0816

FCF/Share

-2.1335

Cash/Share

18.7632

OCF/Sales

-77.3388

FCF/OCF

1.0250

CF Coverage

-22.0062

ST Coverage

-63.1401

CapEx Coverage

-40.0742

Div&CapEx Cov

-40.0742

P/BV

2.0182

P/B

2.0182

P/S

1617.8805

P/E

-18.4831

P/FCF

-20.4101

P/OCF

-18.0727

P/CF

-18.0727

PEG

0.2488

P/S

1617.8805

EV Multiple

-14.5829

P/FV

2.0182

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 20, 23:30 Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671 GlobeNewswire Inc. Jun 05, 23:53 Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering The Motley Fool Dec 25, 07:45 Structure Therapeutics Stock Just Crashed. Here's Why It Could Be Worth Buying Now The Motley Fool Dec 25, 07:45 Structure Therapeutics Stock Just Crashed. Here's Why It Could Be Worth Buying Now The Motley Fool Dec 25, 07:45 Structure Therapeutics Stock Just Crashed. Here's Why It Could Be Worth Buying Now MarketWatch Dec 23, 13:14 Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?  MarketWatch Dec 23, 13:14 Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?  MarketWatch Dec 23, 13:14 Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?  MarketWatch Dec 23, 13:14 Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?  MarketWatch Dec 23, 13:14 Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?  MarketWatch Dec 23, 13:14 Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?  MarketWatch Dec 23, 13:14 Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?  MarketWatch Dec 23, 13:14 Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?  MarketWatch Dec 23, 13:14 Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?  MarketWatch Dec 23, 13:14 Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?  MarketWatch Dec 23, 13:14 Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?  MarketWatch Dec 23, 13:14 Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?  MarketWatch Dec 23, 13:14 Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?  MarketWatch Dec 23, 13:14 Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?  MarketWatch Dec 23, 13:14 Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk? 

Revenue Product Segmentation